Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
100 hedge funds and large institutions have $445M invested in Stemline Therapeutics, Inc. in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 56 increasing their positions, 18 reducing their positions, and 13 closing their positions.
211% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 18
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
4% more funds holding
Funds holding: 96 → 100 (+4)
20% less capital invested
Capital invested by funds: $555M → $445M (-$110M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
69% less call options, than puts
Call options by funds: $292K | Put options by funds: $932K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$20.5M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$20M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$12.7M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$10.5M |
| 5 |
Alkeon Capital Management
New York
|
+$8.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.62M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$6.86M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.52M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.94M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$3.21M |
STML Hedge Fund Activity: Q3 2019 in Review
100 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q3 2019, worth a combined $445M — down 20% from $555M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new STML positions and 13 closed out — a net gain of 4 holders — while 56 added to existing stakes and 18 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $20.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $7.62M.
- 100 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q3 2019, up from 96 in Q2 2019.
- Funds reported $445M of Stemline Therapeutics, Inc. stock for Q3 2019, down 20% quarter-over-quarter.
- 17 funds opened new Stemline Therapeutics, Inc. positions in Q3 2019 and 13 closed out, a net change of +4 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q3 2019 was AllianceBernstein, an estimated $20.5M added.
- The largest Stemline Therapeutics, Inc. seller in Q3 2019 was T. Rowe Price Associates, an estimated $7.62M sold.
Based on aggregated 13F filings for Q3 2019.